Lack of withdrawal signs of dependence following cessation of treatment or Ro-15,1788 administration to rats chronically treated with buspirone.
Failure to gain weight during withdrawal from chronic regimens of dependence-producing drugs is observed in laboratory rats. Withdrawal from the benzodiazepine anxiolytic agent diazepam, whether induced by cessation of treatment or precipitated by administration of the specific benzodiazepine antagonist Ro-15,1788, is accompanied by weight loss. However, the same withdrawal treatments following a chronic regimen of equal doses of the nonbenzodiazepine antianxiety drug buspirone are not associated with weight loss. Buspirone-treated rats gain weight during withdrawal, suggesting that this novel anxiolytic should lack dependence liability in man.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002065:Buspirone; D003975:Diazepam / Q000009:adverse effects; D005442:Flumazenil / Q000494:pharmacology*; D005508:Food Deprivation / Q000502:physiology; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013375:Substance Withdrawal Syndrome
D011743:Pyrimidines; D005442:Flumazenil; D003975:Diazepam; D002065:Buspirone